BETOPTIC- betaxolol hydrochloride solution/ drops


BETOPTIC® Sterile Ophthalmic Solution contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent, in a sterile isotonic solution. Betaxolol hydrochloride is a white, crystalline powder, soluble in water, with a molecular weight of 343.89. The chemical structure is presented below:

Image from Drug Label Content
(click image for full-size original)

Empirical Formula:
C18 H29 NO3 •HCl
Chemical Name:
(±)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride.

Each mL of BETOPTIC Ophthalmic Solution (0.5%) contains: Active: 5.6 mg betaxolol hydrochloride equivalent to betaxolol base 5 mg. Preservative: Benzalkonium Chloride 0.01%. Inactive: Edetate Disodium, Sodium Chloride, Hydrochloric Acid and/or Sodium Hydroxide (to adjust pH), and Purified Water. DM-00


Betaxolol HCl, a cardioselective (beta-1-adrenergic) receptor blocking agent, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Orally administered beta-adrenergic blocking agents reduce cardiac output in healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor antagonists may inhibit the sympathetic stimulatory effect necessary to maintain adequate cardiac function.

When instilled in the eye, BETOPTIC Ophthalmic Solution has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma. Ophthalmic betaxolol has minimal effect on pulmonary and cardiovascular parameters.

Ophthalmic betaxolol (one drop in each eye) was compared to timolol and placebo in a three-way crossover study challenging nine patients with reactive airway disease who were selected on the basis of having at least a 15% reduction in the forced expiratory volume in one second (FEV1 ) after administration of ophthalmic timolol. Betaxolol HCl had no significant effect on pulmonary function as measured by FEV1 . Forced Vital Capacity (FVC) and FEV1 /VC. Additionally, the action of isoproteranol, a beta stimulant, administered at the end of the study was not inhibited by ophthalmic betaxolol. In contrast, ophthalmic timolol significantly decreased these pulmonary functions.

FEV1 — Percent Change From Baseline1
Betaxolol 1.0%a Timolol 0.5% Placebo

1 Schoene, R. B. et al., Am. J. Ophthal. 97:86, 1984.

a Twice the clinical concentration.

b Inhaled at 240 minutes; measurement at 270 minutes.

*Timolol statistically different from betaxolol and placebo (p < 0.05).

Baseline 1.6 1.4 1.4
60 minutes 2.3 -25.7* 5.8
120 Minutes 1.6 -27.4* 7.5
240 Minutes -6.4 -26.9* 6.9
Isoproternolb 36.1 -12.4* 42.8

No evidence of cardiovascular beta-adrenergic blockade during exercise was observed with betaxolol in a double-masked, three-way crossover study in 24 normal subjects comparing ophthalmic betaxolol, timolol and placebo for effect on blood pressure and heart rate. Mean arterial blood pressure was not affected by any treatment; however, ophthalmic timolol produced a significant decrease in the mean heart rate.

Mean Heart Rates1
Bruce Stress Exercise Test
Minutes Betaxolol 1%a Timolol 0.5% Placebo

1 Atkins, J. M. et. al., Am. J. Oph. 99:173-175, Feb., 1985.

a Twice the clinical concentration.

*Mean pulse rate significantly lower for timolol than betaxolol or placebo (p < 0.05).

0 79.2 79.3 81.2
2 130.2 126.0 130.4
4 133.4 128.0* 134.3
6 136.4 129.2* 137.9
8 139.8 131.8* 139.4
10 140.8 131.8* 141.3

Clinical Studies

Optic nerve head damage and visual field loss are the result of a sustained elevated intraocular pressure and poor ocular perfusion. BETOPTIC Ophthalmic Solution has the action of reducing elevated as well as normal intraocular pressure, and the mechanism of ocular hypotensive action appears to be a reduction of aqueous production as demonstrated by tonography and aqueous fluorophotometry. The onset of action with BETOPTIC Ophthalmic Solution can generally be noted within 30 minutes and the maximal effect can usually be detected 2 hours after topical administration. A single dose provides a 12-hour reduction in intraocular pressure. Clinical observation of glaucoma patients treated with BETOPTIC Ophthalmic Solution for up to three years shows that the intraocular pressure lowering effect is well maintained.

Clinical studies show that topical BETOPTIC Ophthalmic Solution reduces mean intraocular pressure 25% from baseline. In trials using 22 mmHg as a generally accepted index of intraocular pressure control, BETOPTIC Ophthalmic Solution was effective in more than 94% of the population studied, of which 73% were treated with the beta blocker alone. In controlled, double-masked studies, the magnitude and duration of the ocular hypotensive affect of BETOPTIC Ophthalmic Solution and ophthalmic timolol solution were clinically equivalent.

BETOPTIC Ophthalmic Solution has also been used successfully in glaucoma patients who have undergone a laser trabeculoplasty and have needed additional long-term ocular hypotensive therapy.

BETOPTIC Ophthalmic Solution has been well tolerated in glaucoma patients wearing hard or soft contact lenses and in aphakic patients.

BETOPTIC Ophthalmic Solution does not produce miosis or accommodative spasm which are frequently seen with miotic agents. The blurred vision and night blindness often associated with standard miotic therapy are not associated with BETOPTIC Ophthalmic Solution. Thus, patients with central lenticular opacities avoid the visual impairment caused by a constricted pupil.

Betoptic Indications and Usage

BETOPTIC Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs.

In clinical studies BETOPTIC was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma.

Page 1 of 2 1 2

All resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.